Supernus Pharmaceuticals, Inc. (SUPN) Bundle
Ever wondered about the story behind Supernus Pharmaceuticals, Inc. and how it operates in the competitive pharmaceutical landscape? Supernus Pharmaceuticals, a biopharmaceutical company specializing in central nervous system (CNS) diseases, reported a 9% increase in full year 2024 revenues, reaching $661.8 million. Keep reading to discover the mission, history, and strategic approach that drives this company, and understand how it innovates and generates revenue in the complex world of CNS treatments.
Supernus Pharmaceuticals, Inc. (SUPN) History
Supernus Pharmaceuticals, Inc. Founding Timeline
Year established
Supernus Pharmaceuticals, Inc. was established in 2005.
Original location
The company is headquartered in Rockville, Maryland.
Founding team members
While specific names of all founding team members are not readily available, Jack Khattar is a key figure as the current President and CEO. He has been with the company since its inception.
Initial capital/funding
Details on the exact initial capital or funding are not specified in the available resources.
Supernus Pharmaceuticals, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2005 | Company Founded | Supernus Pharmaceuticals was founded with a focus on developing and commercializing products for central nervous system (CNS) diseases. |
| 2009 | FDA Approval of Oxtellar XR | Oxtellar XR, an extended-release formulation of oxcarbazepine, was approved by the FDA for the treatment of epilepsy. |
| 2013 | FDA Approval of Trokendi XR | Trokendi XR, an extended-release formulation of topiramate, received FDA approval for the treatment of epilepsy and migraine prevention. |
| 2017 | Acquisition of Vtesse, Inc. | Supernus acquired Vtesse, Inc., adding a rare disease product, Sumavel DosePro, to its portfolio. |
| 2020 | FDA Approval of Qelbree | Qelbree (viloxazine extended-release capsules) was approved by the FDA for the treatment of ADHD in pediatric patients. |
| 2021 | FDA Approval of Qelbree expanded | Qelbree was approved by the FDA for the treatment of ADHD in adults. |
| 2024 | Acquisition of Biotie Therapies Corp. | Supernus Pharmaceuticals finalizes acquisition of Biotie Therapies Corp. |
Supernus Pharmaceuticals, Inc. Transformative Moments
- Focus on CNS Diseases: The company's strategic focus on central nervous system (CNS) diseases has been a key factor in its growth and success.
- FDA Approvals of Key Products: The FDA approvals of Oxtellar XR, Trokendi XR, and Qelbree have been transformative, allowing the company to expand its product offerings and market reach.
- Acquisitions: Strategic acquisitions, such as Vtesse, Inc. and Biotie Therapies Corp, have broadened the company's portfolio and pipeline.
- Expansion into ADHD Market: The approval and launch of Qelbree marked a significant expansion into the ADHD market, opening up new growth opportunities.
To gain more insights into the company's financial performance, check out: Breaking Down Supernus Pharmaceuticals, Inc. (SUPN) Financial Health: Key Insights for Investors
Supernus Pharmaceuticals, Inc. (SUPN) Ownership Structure
Supernus Pharmaceuticals, Inc. features a mixed ownership structure, encompassing institutional, mutual fund, and individual holdings. This blend reflects diverse investment strategies and perspectives on the company's value and future prospects.
Supernus Pharmaceuticals, Inc. Current Status
Supernus Pharmaceuticals, Inc. is a publicly traded company, listed on the NASDAQ Global Select Market under the ticker symbol SUPN. This means that shares of the company are available for purchase by the general public, and the company is subject to the rules and regulations set forth by the U.S. Securities and Exchange Commission (SEC).
Supernus Pharmaceuticals, Inc. Ownership Breakdown
Supernus Pharmaceuticals, Inc.'s ownership is distributed among various types of shareholders. Here's a breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutions | 96.77% | Institutional investors, such as hedge funds, pension funds, and investment banks, hold a significant portion of Supernus Pharmaceuticals, Inc.'s shares. |
| Mutual Funds | 4.38% | Mutual funds also have a stake in the company, indicating its presence in various investment portfolios. |
| Insiders | 0.63% | Company insiders, which includes executives and board members, own a small percentage of the company. |
Supernus Pharmaceuticals, Inc. Leadership
The leadership team at Supernus Pharmaceuticals, Inc. is responsible for guiding the company's strategic direction and overseeing its operations. Here are some of the key figures:
- Jack A. Khattar: President, Chief Executive Officer & Director
- James K. প্যট্রিক: Executive Vice President & CFO
- বাশার রিজভি: President of Research & Development
Understanding the company's mission is crucial, learn more at Mission Statement, Vision, & Core Values of Supernus Pharmaceuticals, Inc. (SUPN).
Supernus Pharmaceuticals, Inc. (SUPN) Mission and Values
Supernus Pharmaceuticals is dedicated to developing and commercializing innovative treatments for central nervous system (CNS) diseases. The company's core values emphasize innovation, patient focus, and integrity in all its operations.
Supernus Pharmaceuticals, Inc. Core Purpose
Official mission statement
Supernus Pharmaceuticals' mission statement is: 'To be a leading global CNS company, driven by innovation, and committed to making a meaningful difference in the lives of patients.'
- Focuses on becoming a leading global entity in the CNS sector.
- Highlights innovation as a key driver.
- Emphasizes a commitment to improving patients' lives.
Vision statement
While a specific, distinct vision statement is not explicitly declared, inferences from various sources suggest the company aims to:
- Establish itself as a leader in CNS treatments through innovative drug development.
- Expand its product portfolio to address a wide range of CNS disorders.
- Improve the standard of care and quality of life for individuals affected by CNS conditions.
Company slogan/tagline
Supernus Pharmaceuticals does not have a widely publicized official slogan or tagline. However, considering their mission and activities, an unofficial tagline could be:
- 'Innovating for the Brain.'
- 'Committed to CNS Solutions.'
- 'Transforming CNS Treatment.'
These potential taglines reflect the company's focus on CNS innovation and patient care. For more insights into Supernus Pharmaceuticals, Inc.'s financial stability and investment potential, check out Breaking Down Supernus Pharmaceuticals, Inc. (SUPN) Financial Health: Key Insights for Investors.
Supernus Pharmaceuticals, Inc. (SUPN) How It Works
Supernus Pharmaceuticals, Inc. focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, aiming to address unmet needs in psychiatry, neurology, and related areas.
Supernus Pharmaceuticals, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Qelbree (viloxazine extended-release capsules) | Children and adults with Attention Deficit Hyperactivity Disorder (ADHD) | Non-stimulant medication, offering an alternative for patients where stimulants are not suitable. Approved for both children (6-17 years) and adults. In 2024, Supernus reported $422.2 million in net product sales for Qelbree. |
| Oxtellar XR (oxcarbazepine extended-release tablets) | Individuals with epilepsy | Once-daily extended-release formulation of oxcarbazepine, designed to control partial seizures. Net product sales for Oxtellar XR were $144.9 million in 2024. |
| Trokendi XR (topiramate extended-release capsules) | Patients with epilepsy or migraine | Extended-release topiramate capsules, providing once-daily administration for seizure control and migraine prevention. Trokendi XR generated net product sales of $115.1 million in 2024. |
| Aptiom (eslicarbazepine acetate) | Individuals with partial-onset seizures | Once-daily anti-epileptic medication. In 2024, Aptiom recorded net product sales of $72.4 million. |
Supernus Pharmaceuticals, Inc.'s Operational Framework
Supernus Pharmaceuticals operates through a focused approach encompassing research and development, clinical trials, regulatory approvals, and commercialization. Here's a breakdown:
- Research and Development: Supernus invests in identifying and developing new therapies and improving existing treatments for CNS disorders.
- Clinical Trials: Rigorous clinical trials are conducted to evaluate the safety and efficacy of their drug candidates.
- Regulatory Approvals: The company seeks approvals from regulatory bodies like the FDA to bring their products to market.
- Manufacturing: Supernus partners with contract manufacturing organizations (CMOs) to manufacture its products.
- Commercialization: A dedicated sales and marketing team promotes and sells the approved medications to healthcare providers and patients.
These operational activities are supported by robust intellectual property management and strategic collaborations.
Supernus Pharmaceuticals, Inc.'s Strategic Advantages
- Focus on CNS Disorders: Specialization allows for deep expertise and targeted drug development.
- Extended-Release Technology: Improves patient compliance and therapeutic outcomes.
- Diverse Product Portfolio: Reduces reliance on any single product.
- Strong Intellectual Property: Protects market exclusivity and fosters innovation.
- Experienced Management Team: Provides strategic direction and operational excellence.
To gain more insights into the values that guide Supernus Pharmaceuticals, Inc., explore: Mission Statement, Vision, & Core Values of Supernus Pharmaceuticals, Inc. (SUPN).
Supernus Pharmaceuticals, Inc. (SUPN) How It Makes Money
Supernus Pharmaceuticals, Inc. generates revenue primarily through the sales of its proprietary pharmaceutical products focused on central nervous system (CNS) disorders. These products include treatments for epilepsy, ADHD, and other neurological conditions.
Supernus Pharmaceuticals, Inc. Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Oxtellar XR® | Approximately 22% of product sales | Decreasing |
| Trokendi XR® | Approximately 15% of product sales | Decreasing |
| Aptiom® | Approximately 14% of product sales | Stable |
| Qelbree® | Approximately 35% of product sales | Increasing |
| Mydayis® | Approximately 14% of product sales | Increasing |
Supernus Pharmaceuticals, Inc. Business Economics
Supernus operates in the pharmaceutical industry, which is characterized by high research and development costs, regulatory hurdles, and strong competition. The company's business economics are influenced by factors such as:
- Pricing Strategy: Supernus employs a premium pricing strategy for its branded medications, which is typical in the pharmaceutical industry to recoup R&D expenses and generate profit.
- Intellectual Property: Patents and exclusivity periods are crucial for maintaining market share and profitability. Supernus relies on these protections to prevent generic competition.
- Market Access: Reimbursement policies by insurance companies and government healthcare programs significantly impact the accessibility and sales volume of Supernus's products.
- R&D Investments: A substantial portion of revenue is reinvested into research and development to discover and commercialize new treatments.
These elements collectively shape Supernus's ability to generate revenue and sustain its operations within the competitive pharmaceutical landscape.
Supernus Pharmaceuticals, Inc. Financial Performance
Analyzing Supernus Pharmaceuticals' financial performance involves looking at key metrics that reflect its operational efficiency and profitability:
- Revenue Growth: Monitoring the growth in sales of key products like Qelbree® and Mydayis® indicates the company's ability to expand its market presence.
- Gross Margin: The gross margin reflects the profitability of Supernus's products after accounting for the cost of goods sold. A healthy gross margin is essential for covering operating expenses and R&D investments. In 2024, Supernus reported a gross margin on product sales of $542.8 million.
- Operating Expenses: Controlling operating expenses, including selling, general, and administrative (SG&A) and research and development (R&D) costs, is critical for achieving profitability.
- Net Income/Loss: The bottom line indicates whether Supernus is generating a profit or incurring a loss. Factors such as product sales, operating expenses, and interest expenses influence net income. For the year 2024, Supernus reported net income of $91.9 million, or $1.66 per diluted share.
- Cash Flow: Positive cash flow from operations is vital for funding ongoing operations, investing in R&D, and pursuing strategic initiatives. In 2024, Supernus had $361.3 million in cash, cash equivalents, and marketable securities.
These financial indicators provide insights into Supernus's financial health and its capacity to sustain growth and innovation in the pharmaceutical market.
Explore more about Supernus Pharmaceuticals, Inc. (SUPN): Exploring Supernus Pharmaceuticals, Inc. (SUPN) Investor Profile: Who’s Buying and Why?
Supernus Pharmaceuticals, Inc. (SUPN) Market Position & Future Outlook
Supernus Pharmaceuticals is navigating a competitive pharmaceutical landscape, focusing on developing and commercializing products for central nervous system (CNS) diseases. Their future outlook hinges on the success of their existing product portfolio and pipeline development.
Competitive Landscape
The competitive landscape for Supernus Pharmaceuticals includes other pharmaceutical companies that develop and market treatments for CNS disorders. Market share data can fluctuate based on product performance, new approvals, and strategic partnerships.
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Supernus Pharmaceuticals | ~2-3% | Specialized focus on CNS disorders; Established products like Trokendi XR and Oxtellar XR. |
| Takeda Pharmaceutical | ~15-17% | Strong global presence and diverse portfolio in CNS, including ADHD treatments. |
| Johnson & Johnson | ~10-12% | Broad healthcare portfolio, including significant CNS medications and research capabilities. |
Opportunities & Challenges
Supernus faces both opportunities and risks that will shape its trajectory in the pharmaceutical industry.
| Opportunities | Risks |
|---|---|
| Expanding product pipeline with successful clinical trials for new CNS therapies. | Clinical trial failures or delays in regulatory approvals for pipeline products. |
| Strategic acquisitions or partnerships to broaden product offerings and market reach. | Generic competition eroding market share of key revenue-generating drugs like Trokendi XR. |
| Increasing demand for CNS treatments due to aging populations and rising awareness of mental health conditions. | Changes in healthcare policies or reimbursement models impacting drug pricing and access. |
Industry Position
Supernus Pharmaceuticals maintains a specific position within the pharmaceutical industry, focusing primarily on central nervous system (CNS) disorders. This specialization allows them to concentrate their research, development, and marketing efforts.
- Specialized Portfolio: Their portfolio includes drugs for epilepsy, ADHD, and other CNS conditions, providing a focused approach to treatment.
- Pipeline Development: Continued investment in R&D is crucial for sustaining their market position with innovative therapies.
- Market Competition: They compete with larger pharmaceutical companies, necessitating strategic partnerships and niche market strategies.
To gain more insight into the values that guide Supernus Pharmaceuticals, explore: Mission Statement, Vision, & Core Values of Supernus Pharmaceuticals, Inc. (SUPN).
Supernus Pharmaceuticals, Inc. (SUPN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.